Maxim Group restated their buy rating on shares of Atossa Genetics (NASDAQ:ATOS) in a research report released on Wednesday morning. The brokerage currently has a $5.00 target price on the stock.

“Atossa reported 3Q18 with a net loss of ($3.3M) and ended the period with $13M in cash on the balance sheet. We estimate Atossa has sufficient runway into 2H19.”,” Maxim Group’s analyst wrote.

Atossa Genetics stock traded up $0.11 during mid-day trading on Wednesday, hitting $1.32. The company’s stock had a trading volume of 12,134 shares, compared to its average volume of 302,132. Atossa Genetics has a 52-week low of $1.12 and a 52-week high of $10.68.

Atossa Genetics (NASDAQ:ATOS) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.01. On average, research analysts forecast that Atossa Genetics will post -4.08 earnings per share for the current year.

About Atossa Genetics

Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.

Read More: Capital gains and your 401(k) or IRA

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.